NEW YORK, NY / ACCESWIRE / August 10, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Tupperware Brands Corporation (NYSE:TUP)
Class Period: November 3, 2021 - May 3, 2022
Lead Plaintiff Deadline: August 15, 2022

Throughout the class period, Tupperware Brands Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Tupperware was facing significant challenges in maintaining its earnings and sales performance; (ii) accordingly, Tupperware's full-year 2022 guidance was unrealistic and/or unsustainable; (iii) all the foregoing, once revealed, was likely to have a material negative impact on Tupperware's financial condition; and (iv) as a result, the Company's public statements were materially false and
misleading at all relevant times.

Learn about your recoverable losses in TUP: https://www.kleinstocklaw.com/pslra-1/tupperware-brands-corporation-loss-submission-form-2?id=30722&from=1

Unilever PLC (NYSE:UL)
This lawsuit is on behalf of all persons who purchased or otherwise acquired Unilever American Depositary Receipts between September 2, 2020 and July 21, 2021, inclusive.
Lead Plaintiff Deadline: August 15, 2022

The complaint alleges Unilever PLC made materially false and/or misleading statements and/or failed to disclose that: a) in July 2020, the board of Ben & Jerry's, one of Unilever's marquee brands, passed a resolution to end sales of its ice cream in 'Occupied Palestinian Territory' ; and b) this boycott decision risked adverse governmental actions for violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states.

Learn about your recoverable losses in UL: https://www.kleinstocklaw.com/pslra-1/unilever-plc-loss-submission-form?id=30722&from=1

TG Therapeutics, Inc. (NASDAQ:TGTX)
Class Period: January 15, 2020 - May 31, 2022
Lead Plaintiff Deadline: September 16, 2022

Throughout the class period, TG Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in TGTX: https://www.kleinstocklaw.com/pslra-1/tg-therapeutics-loss-submission-form?id=30722&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm